CTOs on the Move


 
Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for people living with kidney disease.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.akebia.com
  • 245 First Street Suite 1400
    Cambridge, MA USA 02142
  • Phone: 617.871.2098

Executives

Name Title Contact Details
Michael Crispin
Vice President, Technology and Digital Operations Profile

Similar Companies

WHPM Biotech

WHPM Biotech is a El Monte, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zija International

Zija International is a Lindon, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetica Bio

Synthetica Bio is a privately held healthcare technology company based in Laguna Beach, California that is developing the next generation of safe and secure generative artificial intelligence (GenAI) solutions for the biopharma industry. The Synthetica Bio platform leverages and optimizes multiple large language models (LLMs) and vector databases to ingest real-time data streams and make actionable knowledge directly available to biopharma discovery, clinical, and commercial teams. The platform enables healthcare professionals to rapidly leverage the power of GenAI within compliance of data security standards required by the industry.

Light House Ministries

Light House Ministries is a Lake Bluff, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

10X Genomics

10x Genomics meets the critical need for long range, structural and cellular information, with an innovative system that transforms short-read sequencing technologies. Our Chromium™ System supports comprehensive genomics and high-throughput single cell transcriptomics. It enables researchers to discover previously inaccessible genomic information at unprecedented scale, including phased structural variants, phased single nucleotide variants, and dynamic gene expression of individual cells—while leveraging their existing sequencing systems and workflows.